Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/14417
Title: Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years
Authors: Kulkanya Chokephaibulkit
Wasana Prasitsuebsai
Orasri Wittawatmongkol
Meena Gorowara
Wanatpreeya Phongsamart
Jiratchiya Sophonphan
Stephen J. Kerr
Nirun Vanprapar
Thanyawee Puthanakit
Chayapa Pasomsap
Tulathip Suwanlerk
Vanitha Sekar
David Burger
Jintanat Ananworanich
Mahidol University
The HIV Netherlands Australia Thailand Research Collaboration
University of New South Wales (UNSW) Australia
Chulalongkorn University
Tibotec Inc.
Radboud University Nijmegen Medical Centre
SEARCH
Keywords: Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 10-Dec-2012
Citation: Antiviral Therapy. Vol.17, No.7 (2012), 1263-1269
Abstract: Background: The Asian population, in general, has higher antiretroviral concentrations than those who are not Asian, but there are limited pharmacokinetic data for darunavir/ritonavir in Asian children. Methods: Thai children aged ≥7 years and with body weight (BW)≥20 kg who were on darunavir/ritonavir for ≥2 weeks underwent 12-h pharmacokinetics with blood sampling before and at 1, 2, 4, 6, 8, 10 and 12 h postdosing. Darunavir/ritonavir doses were 375/100 mg twice daily (BW 20 to < 30 kg, n=12), 450/100 mg twice daily (BW 30 to < 40 kg, n=2) or 600/100 mg twice daily (BW ≥40 kg, n=5). Ritonavir 100 mg soft gel capsules were used instead of solution. Results: Of the 19 children, 8 were female, median age was 13 years (range 7-16) and median BW was 29.4 kg. The median duration of darunavir/ritonavir treatment was 11 months. The geometric mean values for darunavir were 60.3 hxmg/l for the area under the concentration-time curve at 0-12 h (AUC 0-12 ), 8.3 mg/l for the maximum concentration (C max ) and 3.1 for the concentration prior to the next dose (C 12 ) with no differences between dosing groups. All had C 12 above the protein binding adjusted 50% effective concentration (EC 50 ) of protease inhibitor-resistant virus (0.55 mg/l). The darunavir pharmacokinetic parameters were similar to those in non-Asian individuals from the DELPHI study, in which 13 of 20 with BW < 40 kg used 50 or 60 mg ritonavir boosting. Conclusions: Thai children aged ≥7 years who were on standard darunavir dosing with 100 mg ritonavir boosting had adequate and comparable darunavir AUC 0-12 , C max and C 12 to non-Asian children who mainly used lower doses of ritonavir boosting. A ritonavir boosting dose of 100 mg can be used for children weighing ≥20 kg, particularly when lower dose formulations are unavailable or if intolerant to the solution. ©2012 International Medical Press.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84870498215&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/14417
ISSN: 20402058
13596535
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.